HIV Drug Lawsuits Consolidated

Pharma Company Pays $10M to Exit Opioid Bellwethers
August 21, 2019
truvada prep patent
Truvada for PrEP Patents Challenged
August 22, 2019
litigation lawsuit court case

Judicial Council Consolidates Gilead Tenofovir Lawsuits in California

More than a dozen lawsuits involving the HIV drug maker Gilead and its tenofovir drugs have been consolidated in state court in California. 

The Chair of the Judicial Council handed down the ruling on August 2 to consolidate 16 cases that accuse Gilead of manufacturing and selling HIV drugs it knew to cause damage to patients’ kidneys and bones. 

The lawsuits also allege that Gilead had developed safer HIV drugs containing a different active ingredient that did not cause the same negative side effects to the kidneys, but chose not to seek approval until the patent on its most popular tenofovir drug, Truvada, was set to run out. 

The lawsuits are now being consolidated in San Francisco Superior Court. A Coordination Trial Judge to oversee the cases is yet to be assigned. 

Consolidation brings together lawsuits that allege similar claims but that are filed in different counties together in one court. It allows attorneys to work together and pool resources in complex litigation with the intention of saving time and court costs.  

The initial coordination involves 16 individual lawsuits, but more tenofovir lawsuits are expected to join in the future. 

Gilead Accused of Selling Harmful HIV Drugs

Gilead HIV drug

The lawsuits against Gilead accuse the company of designing, manufacturing, and selling a defective drug that caused kidney and bone issues in some patients. 

The HIV drugs Truvada and Truvada for PrEP, Viread, Stribild, Complera, and Atripla all contain the active ingredient tenofovir disoproxil fumarate, or TDF.

TDF has been associated with negative complications like chronic kidney disease, kidney failure, bone density loss, fractures, and tooth loss. 

Though these HIV medications have saved thousands of lives and prevented the spread of HIV in thousands more who use it for PrEP, Gilead Tenofovir Cases allege the drug maker had developed a different drug that was just as effective as TDF drugs but without the same negative side effects. 

Did a Safer Alternative Exist?

The HIV drug alternatives Genvoya, Biktarvy, Odefsey, and Descovy contain the active ingredient tenofovir alafenamide fumarate, or TAF. TAF is a prodrug of tenofovir, meaning it doesn’t start working until it is metabolized by the body. 

Because TAF is broken down differently in the body than TDF, it is believed TAF drugs are less harmful and cause fewer negative side effects. 

Despite evidence showing Gilead developed TAF drugs at the same time it developed TDF drugs, the company did not seek approval by the U.S. Food and Drug Administration until the patent for the blockbuster TDF drug, Truvada, was close to running out. 

Profits Over People

Gilead Tenofovir Lawsuits allege Gilead knowingly withheld a safer drug alternative from thousands of people living with HIV until its exclusivity rights over the billion-dollar-drug Truvada ran out. 

Gilead is accused of putting profits over people. TDF drugs Truvada, Truvada for PrEP, Viread, Complera, Stribild, and Atripla are associated with serious side effects such as kidney damage and bone loss. 

If you or someone you love took a TDF drug and developed kidney or bone issues, you may be entitled to financial compensation. Speak with an experienced tenofovir attorney today to see if you qualify for a Gilead Tenofovir Lawsuit. Call 1-800-631-5656 now.